Publicacións (41) Publicacións nas que participase algún/ha investigador/a

filter_list Pharmacology

2024

  1. Benzylhydroxamic acids as inhibitors of insulin regulated aminopeptidase (IRAP)

    European Journal of Medicinal Chemistry Reports, Vol. 12

  2. Discovery of hybrid Glypromate conjugates with neuroprotective activity against paraquat-induced toxicity

    RSC Medicinal Chemistry, Vol. 15, Núm. 11, pp. 3711-3727

  3. Exploring Biginelli-based scaffolds as A2B adenosine receptor antagonists: Unveiling novel structure-activity relationship trends, lead compounds, and potent colorectal anticancer agents

    Biomedicine and Pharmacotherapy, Vol. 173

  4. N-Adamantyl-1-alkyl-4-oxo-1,4-dihydroquinoline-3-carboxamide Derivatives as Fluorescent Probes to Detect Microglia Activation through the Imaging of Cannabinoid Receptor Subtype 2 (CB2R)

    Journal of Medicinal Chemistry, Vol. 67, Núm. 13, pp. 11003-11023

  5. Progress on the development of Class A GPCR-biased ligands

    British Journal of Pharmacology

2023

  1. A Robust and Efficient FRET-Based Assay for Cannabinoid Receptor Ligands Discovery

    Molecules, Vol. 28, Núm. 24

  2. Development of N-(1-Adamantyl)benzamides as Novel Anti-Inflammatory Multitarget Agents Acting as Dual Modulators of the Cannabinoid CB2 Receptor and Fatty Acid Amide Hydrolase

    Journal of Medicinal Chemistry, Vol. 66, Núm. 1, pp. 235-250

  3. Fluorescence based HTS-compatible ligand binding assays for dopamine D3 receptors in baculovirus preparations and live cells

    Frontiers in Molecular Biosciences, Vol. 10

  4. Multicomponent Reaction-Assisted Drug Discovery: A Time- and Cost-Effective Green Approach Speeding Up Identification and Optimization of Anticancer Drugs

    International Journal of Molecular Sciences, Vol. 24, Núm. 7

  5. N-adamantyl-anthranil amide derivatives: New selective ligands for the cannabinoid receptor subtype 2 (CB2R)

    European Journal of Medicinal Chemistry, Vol. 248

  6. Pharmacological insights emerging from the characterization of a large collection of synthetic cannabinoid receptor agonists designer drugs

    Biomedicine and Pharmacotherapy, Vol. 164

  7. Stapling Amantadine to Melanostatin Neuropeptide: Discovery of Potent Positive Allosteric Modulators of the D2 Receptors

    ACS Medicinal Chemistry Letters, Vol. 14, Núm. 12, pp. 1656-1663

2022

  1. Exploring Non-orthosteric Interactions with a Series of Potent and Selective A3Antagonists

    ACS Medicinal Chemistry Letters, Vol. 13, Núm. 2, pp. 243-249

2021

  1. Discovery of New Potent Positive Allosteric Modulators of Dopamine D2Receptors: Insights into the Bioisosteric Replacement of Proline to 3-Furoic Acid in the Melanostatin Neuropeptide

    Journal of Medicinal Chemistry, Vol. 64, Núm. 9, pp. 6209-6220

  2. Identification of V6.51L as a selectivity hotspot in stereoselective A2B adenosine receptor antagonist recognition

    Scientific Reports, Vol. 11, Núm. 1

  3. Potent and Subtype-Selective Dopamine D2Receptor Biased Partial Agonists Discovered via an Ugi-Based Approach

    Journal of Medicinal Chemistry, Vol. 64, Núm. 12, pp. 8710-8726

  4. Similarities and differences upon binding of naturally occurring Δ9-tetrahydrocannabinol-derivatives to cannabinoid CB1 and CB2 receptors

    Pharmacological Research, Vol. 174

2020

  1. Nitrogen-Walk Approach to Explore Bioisosteric Replacements in a Series of Potent A2B Adenosine Receptor Antagonists

    Journal of medicinal chemistry, Vol. 63, Núm. 14, pp. 7721-7739

2019

  1. Synthesis, Pharmacological, and Biological Evaluation of MIF-1 Picolinoyl Peptidomimetics as Positive Allosteric Modulators of D2R

    ACS Chemical Neuroscience, Vol. 10, Núm. 8, pp. 3690-3702

  2. Trifluorinated Pyrimidine-Based A2B Antagonists: Optimization and Evidence of Stereospecific Recognition

    Journal of Medicinal Chemistry, Vol. 62, Núm. 20, pp. 9315-9330